{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gonadotrophin-releasing+Hormone+%28GnRH%29",
    "query": {
      "condition": "Gonadotrophin-releasing Hormone (GnRH)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 51,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gonadotrophin-releasing+Hormone+%28GnRH%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:58:59.790Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02663908",
      "title": "A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 545,
      "start_date": "2016-04-19",
      "completion_date": "2021-03-29",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663908"
    },
    {
      "nct_id": "NCT00667446",
      "title": "Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Precocious",
        "Leuprolide Acetate",
        "Luteinizing Hormone (LH)",
        "Gonadotrophin-releasing Hormone Agonist (GnRHa)",
        "Tanner Staging",
        "Depot Formulation",
        "Suppression of LH",
        "Central Precocious Puberty (CPP)",
        "Gonadotrophin-releasing Hormone (GnRH)",
        "Lupron",
        "GnRH Analog",
        "Pediatrics Central Precocious Puberty"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate 3 Month Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 72,
      "start_date": "2008-12",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-01-09",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667446"
    },
    {
      "nct_id": "NCT06631521",
      "title": "Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate CA",
        "Prostate Cancer (Adenocarcinoma)",
        "Prostate Cancer Surgery"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "AdventHealth",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2024-10-22",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06631521"
    },
    {
      "nct_id": "NCT01023061",
      "title": "Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Stage II Prostate Cancer",
        "Stage III Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "external beam radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "goserelin acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2010-03",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-06-06",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington • Tacoma, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01023061"
    },
    {
      "nct_id": "NCT05567198",
      "title": "Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus (Sle)",
        "Primary Ovarian Insufficiency (Poi)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2023-03-03",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567198"
    },
    {
      "nct_id": "NCT00254397",
      "title": "Melanoma Vaccine With Peptides and Leuprolide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "GP100: 209-217(210M) Peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAGE-3 Peptide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2005-11",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2019-10-16",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00254397"
    },
    {
      "nct_id": "NCT01088529",
      "title": "Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "LHRHa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cougar Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 66,
      "start_date": "2009-12",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-05-15",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088529"
    },
    {
      "nct_id": "NCT00429494",
      "title": "GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amenorrhea",
        "Premature Ovarian Failure",
        "Ovarian Function Insufficiency"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "Up to 40 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2002-11",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2013-07-09",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00429494"
    },
    {
      "nct_id": "NCT00004335",
      "title": "Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypogonadism",
        "Precocious Puberty"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "7 Years to 35 Years"
      },
      "enrollment_count": null,
      "start_date": "1993-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004335"
    },
    {
      "nct_id": "NCT01976728",
      "title": "LutrePulse Hypogonadotropic Hypogonadism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Amenorrhea With Hypogonadotropic Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump",
          "type": "DRUG"
        },
        {
          "name": "Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump",
          "type": "DRUG"
        },
        {
          "name": "Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump",
          "type": "DRUG"
        },
        {
          "name": "Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 39,
      "start_date": "2014-04-01",
      "completion_date": "2018-02-23",
      "has_results": true,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-05-22T04:58:59.790Z",
      "location_count": 33,
      "location_summary": "Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01976728"
    }
  ]
}